p.80 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

April 1, 2025 Circulation. 2025;151:e771–e862. DOI: 10.1161/CIR.0000000000001309 e850

19.	 Morrow DA, Fang JC, Fintel DJ, et al. Evolution of critical care cardiology: transformation of the cardiovascular intensive care unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association. Circulation. 2012;126:1408–1428. 20.	 Papolos AI, Kenigsberg BB, Berg DD, et al. Management and outcomes of cardiogenic shock in cardiac ICUs with versus without shock teams. J Am Coll Cardiol. 2021;78:1309–1317. 21.	 Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol. 2019;73:1659–1669. 22.	 Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol. 2000;36:1117– 1122. 23.	 Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we use emergently revascularize occluded coronaries in cardiogenic shock? J Am Coll Cardiol. 2000;36:1104–1109. 24.	 Valle JA, Miyasaka RL, Carroll JD. Acute mitral regurgitation secondary to papillary muscle tear: is transcatheter edge-to-edge mitral valve repair a new paradigm? Circ Cardiovasc Interv. 2017;10:e005050. 25.	 Thiele H, Lauer B, Hambrecht R, et al. Short and long-term hemodynamic effects of intra-aortic balloon support in ventricular septal defect complicating acute myocardial infarction. Am J Cardiol. 2003;92:450–454. 26.	 Damluji AA, van Diepen S, Katz JN, et al. Mechanical complications of acute

myocardial infarction: a scientific statement from the American Heart Association. Circulation. 2021;144:e16–e35. 9.2. Electrical Complications and Prevention of Sudden Cardiac Death After ACS 1.	 Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940. 2.	 Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883. 3.	 Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225– 237. 4.	 Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882– 1890. 5.	 Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588. 6.	 Zaman S, Sivagangabalan G, Narayan A, et al. Outcomes of early risk stratification and targeted implantable cardioverter-defibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation. 2009;120:194–200. 7.	 Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379:1205–1215. 8.	 Kim H-L, Kim S-H, Seo J-B, et al. Influence of second-and third-degree heart block on 30-day outcome following acute myocardial infarction in the drug-eluting stent era. Am J Cardiol. 2014;114:1658–1662. 9.	 Wang P, Wang S, Liu Z, et al. Prognostic value of temporary pacemaker insertion in patients with acute myocardial infarction in the era of percutaneous coronary revascularization. Rev Cardiovasc Med. 2023;24:179. 10.	 Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/ HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of ardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1–e156. 11.	 Thomsen AF, Jacobsen PK, Koeber L, et al. Risk of arrhythmias after myocardial infarction in patients with left ventricular systolic dysfunction according to mode of revascularization: a Cardiac Arrhythmias and RIsk Stratification after Myocardial infArction (CARISMA) substudy. EP: Europace. 2021;23:616–623. 12.	 Rymer JA, Wegermann ZK, Wang TY, et al. Ventricular arrhythmias after primary percutaneous coronary intervention for STEMI. JAMA Netw Open. 2024;7:e2410288. 13.	 Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify

patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000;342:1937–1945. 14.	 Bigger JT Jr, CABG Patch Trial Investigators. Prophylactic use of implanted

cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569–1575. 15.	 Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488. 16.	 Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–1436. 17.	 Podolecki T, Lenarczyk R, Kowalczyk J, et al. Prognostic significance of complex ventricular arrhythmias complicating ST-segment elevation myocardial infarction. Am J Cardiol. 2018;121:805–809. 18.	 Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014;130:94–125. 19.	 Komatsu Y, Hocini M, Nogami A, et al. Catheter ablation of refractory ventricular fibrillation storm after myocardial infarction. Circulation. 2019;139:2315–2325. 20.	 Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140:e382–e482. 21.	 Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and perprotocol analyses. J Cardiovasc Electrophysiol. 2020;31:1009–1018. 22.	 Kim KH, Jeong MH, Ahn Y, et al. Differential clinical implications of highdegree atrioventricular block complicating ST-segment elevation myocardial infarction according to the location of infarction in the era of primary percutaneous coronary intervention. Korean Circ J. 2016;46:315–323. 23.	 Auffret V, Loirat A, Leurent G, et al. High-degree atrioventricular block complicating ST segment elevation myocardial infarction in the contemporary era. Heart. 2016;102:40–49. 24.	 Aguiar Rosa S, Timoteo AT, Ferreira L, et al. Complete atrioventricular block in acute coronary syndrome: prevalence, characterisation and implication on outcome. Eur Heart J Acute Cardiovasc Care. 2018;7:218–223. 25.	 Gang UJ, Hvelplund A, Pedersen S, et al. High-degree atrioventricular block complicating ST-segment elevation myocardial infarction in the era of primary percutaneous coronary intervention. Europace. 2012;14:1639–1645. 26.	 Alnsasra H, Ben-Avraham B, Gottlieb S, et al. High-grade atrioventricular block in patients with acute myocardial infarction. Insights from a contemporary multi-center survey. J Electrocardiol. 2018;51:386–391. 27.	 Singh SM, FitzGerald G, Yan AT, et al. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. Eur Heart J. 2015;36:976–983. 28.	 Pokorney SD, Radder C, Schulte PJ, et al. High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-STsegment elevation myocardial infarction. Am Heart J. 2016;171:25–32. 29.	 Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary

pacemaker therapy in the coronary care unit. Mayo Clin Proc. 1983:122–126. 9.3. Pericarditis Management After MI 1.	 Gouriet F, Levy PY, Casalta JP, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med. 2015;128:784.e781–e788. 2.	 Imazio M, Brucato A, Rovere ME, et al. Contemporary features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol. 2011;108:1183–1187. 3.	 Imazio M, Negro A, Belli R, et al. Frequency and prognostic significance of pericarditis following acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol. 2009;103:1525–1529. 4.	 Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am Heart J. 1981;101:750–753. 5.	 Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987–1991. 6.	 Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–414. 7.	 Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treat-

ment of multiple recurrences of pericarditis (CORP-2): a multicentre, dou-

Downloaded from http://ahajournals.org by on October 7, 2026